SABCS 2021 | Key clinical trials in breast cancer presented at SABCS 2021

Diogo Martins-Branco, MD, MSc, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium, highlights the current key clinical trials in breast cancer at the San Antonio Breast Cancer Symposium 2021. Trials mentioned include the Phase II NIMBUS (NCT03789110) trial, which demonstrated activity of immune checkpoint inhibitors in patients with breast cancer with high tumor burden. The Phase III SOPHIA (NCT02492711) trial was shown to reinforce the significance of sequencing in metastatic breast cancer, advocating the use of technology to improve personalized treatment for patients with metastatic breast cancer. Dr. Martins-Branco reveals a novel finding was discovered in the Phase III EMERALD (NCT03778931) trial, showing prospective evidence for elacestrant as a superior alternative to the standard of care. Lastly, a trial is described in which the the TROP2-directed antibody-drug conjugate (ADC), datopotamab deruxtecan, demonstrated activity in triple negative breast cancer (TNBC), results that may play a significant role in the future for patients with TNBC. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.